Log in

NASDAQ:SCYXSCYNEXIS Stock Price, Forecast & News

$0.81
+0.04 (+5.19 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.77
Now: $0.81
$0.86
50-Day Range
$0.55
MA: $0.86
$1.15
52-Week Range
$0.50
Now: $0.81
$1.90
Volume533,732 shs
Average Volume692,280 shs
Market Capitalization$78.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.82
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Read More
SCYNEXIS logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SCYX
CUSIPN/A
Phone201-884-5485

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120,000.00
Book Value$0.13 per share

Profitability

Net Income$-53,710,000.00

Miscellaneous

Employees24
Market Cap$78.91 million
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.


SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

How has SCYNEXIS's stock been impacted by COVID-19 (Coronavirus)?

SCYNEXIS's stock was trading at $0.7802 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SCYX stock has increased by 3.8% and is now trading at $0.81. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of SCYNEXIS?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SCYNEXIS.

When is SCYNEXIS's next earnings date?

SCYNEXIS is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for SCYNEXIS.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS Inc (NASDAQ:SCYX) issued its quarterly earnings data on Wednesday, March, 11th. The company reported ($0.22) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.03. View SCYNEXIS's earnings history.

What price target have analysts set for SCYX?

6 equities research analysts have issued 1-year price targets for SCYNEXIS's stock. Their forecasts range from $3.50 to $6.00. On average, they expect SCYNEXIS's stock price to reach $4.63 in the next year. This suggests a possible upside of 471.0% from the stock's current price. View analysts' price targets for SCYNEXIS.

What are Wall Street analysts saying about SCYNEXIS stock?

Here are some recent quotes from research analysts about SCYNEXIS stock:
  • 1. According to Zacks Investment Research, "SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. " (3/18/2020)
  • 2. Needham & Company LLC analysts commented, "Scynexis reported 1Q19 financial results this wk and we spoke w/ mgmt for an update. Enrollment in ibrexafungerp Phase 3 VANISH program in Acute Vulvovaginal Candidiasis (VVC) is progressing and mgmt reiterated guidance for top-line results in 1H20. Phase 3 CANDLE trial in Recurrent VVC is expected to start in 2Q19 (unch). Reiterate BUY. We believe commercial opportunity in VVC is substantially underappreciated by investors given there are no oral options for pts w/ poor response to standard of care oral fluconazole. Recent encouraging data from FURI and CARES trials demonstrating impressive activity against challenging infections (including tied to C. auris) enhances overall profile." (5/12/2019)

Has SCYNEXIS been receiving favorable news coverage?

News coverage about SCYX stock has trended very negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. SCYNEXIS earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutSCYNEXIS.

Who are some of SCYNEXIS's key competitors?

What other stocks do shareholders of SCYNEXIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Cerus (CERS), Novavax (NVAX), Viking Therapeutics (VKTX), Nabriva Therapeutics (NBRV), Verastem (VSTM), Micron Technology (MU), Trevena (TRVN), Agile Therapeutics (AGRX), Advanced Micro Devices (AMD) and Synergy Pharmaceuticals (SGYP).

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the following people:
  • Marco Taglietti, President, Chief Executive Officer & Director
  • Eric Francois, Chief Financial Officer
  • David Angulo Gonzalez, Chief Medical Officer
  • Rajeshwar Motheram, Vice President-Pharmaceutical Development
  • Scott Sukenick, General Counsel

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $0.81.

How big of a company is SCYNEXIS?

SCYNEXIS has a market capitalization of $78.91 million and generates $120,000.00 in revenue each year. The company earns $-53,710,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. SCYNEXIS employs 24 workers across the globe. View additional information about SCYNEXIS.

What is SCYNEXIS's official website?

The official website for SCYNEXIS is http://www.scynexis.com/.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel